| iMTA has ample experience in a variety of major neurological indications, including Multiple Sclerosis, Alzheimer’s disease, migraine and epilepsy. In epilepsy, iMTA ran the EPISODE trial, assessing the effectiveness and cost-effectiveness of epilepsy support dogs. |
iMTA performed a costing study for intrathecal baclofen therapy against spasms, also occurring in multiple sclerosis. The pump was fitted in a home based situation to avoid that patients have to return to the hospital.
In addition, iMTA performed a costing study into the costs of institutionalization of patients with Alzheimer's disease. The results of this study can be used to inform cost-effectiveness studies of future disease modifying treatments for Alzheimer's disease.
iMTA has, together with Erasmus MC, developed a disease model for MS. With this model, the effectiveness and cost-effectivenss of 360 disease-modifying treatment escalation sequences in MS can be assessed. This disease model is being used in the clinical guidelines.
As part of the EPISODE study, iMTA has developed a cost-effectiveness model. A microcosting simulation model was developed to extrapolate the findings beyond the 3-year trial follow-up to cover the average duration of a seizure dog partnership.
iMTA developed the condition specific MSIS-PBM, a preference based instrument based on the Multiple Sclerosis Impact Scale 29. Using the Time Trade-off method in about 400 group interviews in The Netherlands, a selection of items (selected using Rasch-analysis and expert opinion) of the MSIS-29 was weighted. The resulting instrument is more sensitive than EQ5D for minor impairments and better discriminates between patients with EDSS score 3,4 and 5 than EQ5D. Utilities can be calculated from the MSIS-29 directly.